The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public warning over the circulation of a tampered or revalidated batch of SMA Gold First Infant Milk Formula (900g tin) discovered in Kaduna State.

In Public Alert No. 06/2026 shared on its official X handle on Sunday, the agency disclosed that the affected product bears batch number 22939510A1206, with a manufacturing date of January 20, 2025, and an expiry date fraudulently extended to January 20, 2027. The product also carries NAFDAC registration number B1-2783, which corresponds to the genuine SMA Gold 1 formula produced for the Nigerian market by Nestlé.

According to NAFDAC, the issue came to light after the formula was allegedly linked to gastrointestinal distress in a four-month-old infant who consumed it.

A physical inspection of the sample revealed clear signs of date manipulation. The agency noted that the manufacturing and expiry dates printed on a sticker affixed to the top of the tin were inconsistent with the original dates underneath, confirming suspicions of tampering and unlawful shelf-life extension.

NAFDAC explained that SMA Gold Infant Formula is a whey-dominant product formulated to closely resemble the nutritional composition of breast milk for babies aged zero to six months. It warned that any unauthorised alteration of expiry dates compromises product safety and poses significant health risks to infants.

The agency further emphasised that false date markings mislead consumers about a product’s freshness and nutritional value. Expired infant formula, it cautioned, may contain harmful microbial contamination and degraded nutrients, which can be particularly dangerous for infants with developing immune systems.

NAFDAC has directed its zonal directors and state coordinators to intensify surveillance efforts and ensure the removal of the affected product from circulation. Distributors, retailers, healthcare providers, and caregivers have been advised to purchase products only from authorised suppliers and to carefully verify authenticity.

Consumers and healthcare professionals are encouraged to report any adverse reactions or suspicious sales to the nearest NAFDAC office, through the Med-Safety mobile app, the e-reporting portal on the agency’s website, or via email at pharmacovigilance@nafdac.gov.ng.

The agency reiterated its commitment to protecting public health and ensuring that all regulated products in Nigeria meet established standards of quality, safety, and efficacy.